December 24, 2013 —
In an Opinion piece for the Washington Post, Dr. Collins explains how extraordinary discoveries in biomedical research are within reach and investing in NIH’s mission is priceless. Washington Post.
December 17, 2013 —
In The Atlantic, Dr. Collins reflects on the funding challenges from 2013 sequester cuts and how a continued lack of investment in biomedical research may curb opportunities for U.S. leadership in the field. The Atlantic.
December 12, 2013 —
In The Wall Street Journal’s 12 Months of Reading, Dr. Collins recommends that young scientists read Mario Livio's "Brilliant Blunders," which makes a point that scientific blunders can in fact be opportunities rather than setbacks. The Wall Street Journal.
December 3, 2013 —
The Washington Post Editorial Board explains how funding biomedical research pays a generous return on investment in dollars and in lives saved. Editorial Board. The Washington Post.
November 18, 2013 —
Dr. Collins and FDA Commissioner Dr. Margaret Hamburg author an article in the Perspective section of the New England Journal of Medicine, about FDA’s landmark decision to grant marketing authorization for a next-generation sequencer. The article explores how bringing this technology into use for clinical care will transform patient engagement, increase the use of genetic information in health care, and expand research. Collins, Francis S. M.D., Ph.D., and Hamburg, Margaret A., M.D. New England Journal of Medicine.
September 24, 2013 —
Dr. Collins notes that new ideas on cancer, diabetes, autism and heart disease will go unfunded in Thomas Friedman’s New York Times Op-Ed on the state of science in the U.S. New York Times.
August 22, 2013 —
In a one-on-one interview with the Huffington Post, Dr. Collins emphasizes the value of funding scientific research and explains why the sequester impact is worse than predicted. Huffington Post.